Particularly, gain of function of KIT and loss of function of SPTBN5 genes compared with corresponding neutral CNV statuses of KIT and SPTBN5 genes respectively are associated with worse prognosis of IR-treated GBM patients. The gene discussed is SPTBN5; the disease is glioblastoma.